Global Cell-Free DNA (cfDNA) Kits Market Growth Accelerates: Strategic Forecast Predicts $2.85 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Cell-Free DNA (cfDNA) Kits Industry Market Size Be by 2025?
In recent times, the market size for cell-free DNA (cfDNA) kits has seen a significant expansion. The market is set to grow from a value of $1.60 billion in 2024 to $1.80 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. Several factors have contributed to this growth in the historic period, including the escalating number of diagnostic laboratories, a surge in the use of oncology applications, an increment in the adoption of transplantation and gynecology applications, and the prevalent implementation of artificial intelligence in diagnostics.

What's the Long-Term Growth Forecast for the Cell-Free DNA (cfDNA) Kits Market Size Through 2029?
The market size for cell-free DNA (cfDNA) kits is projected to expand significantly in the coming years. It is anticipated to reach a value of $2.86 billion by 2029, with a compound annual growth rate (CAGR) of 12.3%. This projected growth within the forecast period is due to factors such as an increase in the use of digital polymerase chain reaction, more adoption of real-time polymerase chain reaction, a rise in the usage of other disease application conditions, an escalating number of diagnostic labs, and an increased demand for non-invasive prenatal testing. The key trends during the forecast period will be novel developments in single-cell genomics, provision of automated lab workflows, advancements in proteomics-based diagnostics, metabolomics analysis innovation, and development in enzyme-free nucleic acid detection methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-kits-global-market-report

What Are the Key Growth Drivers Fueling the Cell-Free DNA (cfDNA) Kits Market Expansion?
The cell-free DNA (cfDNA) kits market is predicted to grow spurred by the increasing occurrences of genetic disorders. These medical conditions occur due to alterations in individual's DNA, stemming from a single gene mutation, multiple gene mutations, or abnormalities in chromosomes. Lifestyle changes and environmental factors such as pollution and unhealthy eating patterns contribute to the increased incidence of these disorders by causing genetic mutations or worsening inherited conditions. Cell-free DNA (cfDNA) kits facilitate early and non-invasive detection of such genetic irregularities, by examining DNA fragments from blood or other bodily fluids. This enables expedient identification of the condition, assisting healthcare professionals in making prompt and accurate treatment choices. For instance, data from the US-based government agency, the Centers for Disease Control and Prevention (CDC) in November 2024 indicates about 1 in 33 newborns in the US are born with a birth defect, many of which are tied to genetic factors. As such, the increasing occurrence of genetic disorders is propelling the growth of the cell-free DNA (cfDNA) kits market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28161&type=smp

What Are the Key Trends Driving Cell-Free DNA (cfDNA) Kits Market Growth?
Key players in the cell-free DNA (cfDNA) kit industry are focusing on innovations leading to the creation of enhanced products equipped with digital PCR-based absolute quantification, aimed at amplifying the precision and sensitivity of cfDNA analysis. Digital PCR-based absolute quantification permits highly precise detection of rare genetic alterations and increased reliability, which are crucial in cancer screening, prenatal examinations, and monitoring transplant rejection. For example, in June 2024, HoloGRAFT ONE, a research-use-only kit intended for post-transplant supervision of donor-derived cell-free DNA (dd-cfDNA), was rolled out by Omixon, a molecular diagnostics firm based in Hungary. The kit uses proprietary genetic markers and digital PCR to differentiate donor DNA from patient DNA, gauging both dd-cfDNA's absolute and relative quantities via copy-number variants. This groundbreaking test focuses on facilitating early recognition of transplant rejection, augmenting patient supervision, and enabling personalized care post-transplant by offering medical practitioners precise, actionable cfDNA evaluations.

How Is the Cell-Free DNA (cfDNA) Kits Market Segmented?
The cell-free dna (cfDNA) kits market covered in this report is segmented as

1) By Product Type: Plasma Cell-Free DNA (Cfdna) Kits, Serum Cell-Free DNA (Cfdna) Kits, Urine Cell-Free DNA (Cfdna) Kits, Other Products
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray Technology, Digital Polymerase Chain Reaction(PCR)
3) By Application: Cancer Diagnostics, Prenatal Testing, Transplant Rejection Monitoring, Non-Invasive Disease Detection
4) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Sales, Distributors
5) By End User: Hospitals, Research Laboratories, Diagnostic Laboratories, Academic Institutions

Subsegments:
1) By Plasma Cell-Free DNA Kits: Single-Stranded DNA Kits, Double-Stranded DNA Kits, High-Sensitivity DNA Kits, Rapid Extraction DNA Kits
2) By Serum Cell-Free DNA Kits: Low-Volume DNA Kits, High-Yield DNA Kits, Automated DNA Kits, Manual Extraction DNA Kits
3) By Urine Cell-Free DNA Kits: Early Detection DNA Kits, Concentration DNA Kits, High-Purity DNA Kits, Long-Term Stability DNA Kits
4) By Other Products: Saliva DNA Kits, Cerebrospinal Fluid DNA Kits, Amniotic Fluid DNA Kits, Tissue-Derived DNA Kits

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28161&type=smp

Which Companies Are Leading the Charge in Cell-Free DNA (cfDNA) Kits Market Innovation?
Major companies operating in the cell-free dna (cfdna) kits market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Guardant Health Inc., Bioneer Corporation, Streck Inc., Freenome Holdings Inc., GRAIL Inc., Zymo Research Corporation, Geneseeq Technology Inc, Covaris LLC, Active Motif Inc., Norgen Biotek Corp, AMSBIO LLC, EpiGentek Group Inc., Paragon Genomics Inc., Suzhou Beaver Biomedical Engineering.

Which Regions Are Leading the Global Cell-Free DNA (cfDNA) Kits Market in Revenue?
North America was the largest region in the cell-free DNA (cfDNA) kits market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cell-free DNA (cfDNA) kits report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28161

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.